Cellular Dynamics International Opens Facility in California
News Apr 02, 2013
Cellular Dynamics International (CDI) announced that the company is opening a facility in Novato, Calif, leasing space from the Buck Institute for Research on Aging. This opening of a second CDI facility is in response to the company receiving a $16 million grant award from the California Institute of Regenerative Medicine (CIRM) to create and bank human induced pluripotent stem cells (iPSCs). CDI is a leading commercial producer of human induced pluripotent stem cell (iPSC) lines and tissue cells for drug discovery, safety, stem cell banking and cellular therapeutics.
CDI signed a lease for up to five-years in the Buck Institute’s partially CIRM-funded stem cell research building. A portion of the space will be subleased to the Coriell Institute for Medical Research to construct a stem cell bank, an activity for which CDI is a subcontractor.
“The CIRM grants provide CDI with the funding to build, with our partner Coriell, the premier iPSC bank,” said Bob Palay, CDI Chief Executive Officer. “We are excited to be working with the Buck Institute, constructing our stem cell derivation laboratories as well as the stem cell bank within their world class facilities.”
“We are very enthusiastic about partnering with CDI,” said Brian Kennedy, PhD, President and Chief Executive Officer of the Buck Institute. “As a pioneer in stem cell technology, CDI is a perfect tenant for our new Regenerative Medicine Research Center. Their work and this new initiative have the potential to revolutionize the treatment of a myriad of diseases – we are proud they chose to work with us and we are looking forward to collaborating on new research.”
Tom Novak, Ph.D., Vice President of Strategic Partnerships at CDI, said, “Our location in the Buck Institute, with its focus on improving human “healthspan” and researching age-related disease, is a great opportunity for us to interact and collaborate with the top academic scientists in the field. We see this as a great opportunity to draw top talent to CDI’s second location.”
Scleroderma Study Offers New Hope For SufferersNews
An unusual autoimmune disease that causes skin and lung damage can be treated effectively by stem cell transplant, a new study found. The approach could represent the first new treatment to improve survival in patients with severe scleroderma in more than four decades.READ MORE